Form 1 2023 CARE Feedback survey

Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery (NIH)

2023 CARE Feedback Survey

Connecting Awardees with Regulatory Experts (CARE) – Feedback Survey (NCI)

OMB: 0925-0648

Document [pdf]
Download: pdf | pdf
OMB No.: 0925-0648
Expiration Date: 06/30/2024
The Public Health Service Act, Section 411 (42 USC 285a) allows the collection this information. The rights of participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing at any time. Refusal to participate will not affect
your benefits in any way. The information collected will be kept private to the extent provided by law. Names and other identifiers will not appear in any report. Information provided will be combined for all participants and reported as summaries. You are being contacted by email to complete this
form so that NCI can improve the progam.
The public reporting burden for this information collection is estimated to average 3 minutes per response, including reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. An agency may not conduct
or sponsor, and a person is only required to respond to, a collection of information if it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to NIH, Project
Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

2023	NIH	Small	Business	Program	with	FDA
CARE	–	Connecting	Awardees	with	Regulatory	Experts
* 1.	Company	Information
Company	Name
Contact	Person
Title/Role
Email

* 2.	Please	indicate	the	extent	to	which	you	agree	with	the	following.	Participation	in	the
CARE	Program	helped	our	team…
Strongly	Agree
Learn	and/or	confirm	the	FDA	Center
(CBER,	CDER,	CDRH)	or	Office	that	will
regulate	our	technology
Begin	developing	the	regulatory	strategy
for	our	technology
Plan	the	next	regulatory	step(s)	for	our
technology
Clarify	and/or	confirm	the	appropriate
regulatory	path	for	our	technology
Gain	a	better	understanding	of	the	process
to	contact	FDA	for	a	meeting	request
Find	information	on	FDA’s	website	related
to	a	particular	regulatory	topic
Understand	how	to	contact	an	FDA	office
that	provides	free	resource	assistance	to
industry	(i.e.,	MATTB,	SBIA,	or	DICE)

Agree

Disagree

Strongly
Disagree

*	3.	Please	indicate	the	extent	to	which	you	agree	with	the	following.	Following	the	CARE
Program,	our	team	plans	to…	
	

Strongly	Agree

Agree

Disagree

Strongly
Disagree

Contact	an	FDA	office	via	phone	or	email	that
provides	free	resource	assistance	to	industry	(i.e.,
MATTB,	SBIA,	or	DICE)
Watch	an	FDA	webinar(s)	on	a	particular
regulatory	topic
Read	an	FDA	guidance(s)	on	a	particular
regulatory	topic
Access	an	FDA	website	to	learn	more	on	a
particular	regulatory	topic
Submit	a	meeting	request	to	FDA	to	discuss
regulatory	strategy	(e.g.,	INTERACT	meeting,
pre-IND	meeting,	pre-submission	meeting,	etc.)
Hire	a	regulatory	consultant	or	other	personnel	to
help	with	the	team's	regulatory	strategy
Schedule	a	free	regulatory	consultation	with	an
NIH	Regulatory	Specialist	
https://seed.nih.gov/support-for-smallbusinesses/commercialization-enhancementprograms/entrepreneurialdevelopment#innovator-consultations	
or
https://www.nhlbi.nih.gov/about/divisions/divisionextramural-research-activities/office-translationalalliances-and-coordination

*	4.	Please	indicate	the	extent	to	which	you	agree	with	the	following.	Our	team…	
	

Strongly	Agree

Agree

Disagree

Found	the	CARE	Program	useful
Found	the	NCI	SBIR	FDA	resources	website
useful	https://sbir.cancer.gov/resources/fdaresources
Received	information	from	the	CARE
Program	that	will	affect	our	future
SBIR/STTR	specific	aims
Would	recommend	the	CARE	Program	to
other	companies

5.	We	welcome	any	additional	feedback	or	comments	you	wish	to	provide.	

Strongly
Disagree


File Typeapplication/pdf
File Modified2023-03-07
File Created2023-03-07

© 2024 OMB.report | Privacy Policy